EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases

Salvatore Caponnetto, Ornella Cantale, Alex Friedlaender, Fabio Gomes, Sunil Daryanani, Alain Gelibter, Alessio Cortellini, Dario Giuffrida, Alfredo Addeo, Giuseppe Luigi Banna

Journal of Molecular Pathology · 2021

DOI: 10.3390/jmp2010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Pathology, 2021. Verfasst von Salvatore Caponnetto und 9 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the efficacy of different-generation EGFR-tyrosine kinase inhibitors (TKI) on BMs from NSCLC are currently limited. We identified studies comparing different EGFR-TKIs for NSCLC through Pubmed literature search and selected those with neurological outcome data. By two retrospective analyses, Erlotinib showed longer neurological time-to-progression (30 months vs. 15.8 months, P = 0.024) and reduced the risk of central nervous system (CNS) progression (Hazard Ratio (HR) 0.25; 95% CI, 0.08–0.81; P = 0.021) compared to Gefitinib. In a phase 2b randomized trial, 16% of patients with BMs had a similar Progression Free Survival (PFS) (HR 0.76, 95% CI 0.41–1.44) or Overall Survival (OS) (HR 1.16, 95% CI 0.61–2.21) with Afatinib versus Gefitinib; a lower risk of developing subsequent BMs with Afatinib than Gefitinib (HR 0.49; 95% CI 0.34–0.71; P < 0.001) was reported by a retrospective study. A randomized phase 3 trial proved that patients with BMs treated with Osimertinib had longer PFS (HR 0.47, 95% CI 0.30–0.74) and OS (HR 0.79, 95% CI 0.61–1.01) than with Gefitinib, and lower incidence of CNS progression (6% vs. 15%, respectively). Although there is limited evidence, differences in CNS activity may exist between EGFR-TKIs.

Zitieren

APA

Caponnetto, S., Cantale, O., Friedlaender, A., Gomes, F., Daryanani, S., Gelibter, A., Cortellini, A., Giuffrida, D., Addeo, A., & Banna, G. L. (2021). A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology. https://doi.org/10.3390/jmp2010001

Vancouver

Caponnetto S, Cantale O, Friedlaender A, Gomes F, Daryanani S, Gelibter A, et al. A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology. 2021. doi:10.3390/jmp2010001

BibTeX
@article{Caponnetto2021,
  author = {Caponnetto, Salvatore and Cantale, Ornella and Friedlaender, Alex and Gomes, Fabio and Daryanani, Sunil and Gelibter, Alain and Cortellini, Alessio and Giuffrida, Dario and Addeo, Alfredo and Banna, Giuseppe Luigi},
  title = {A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases},
  journal = {Journal of Molecular Pathology},
  year = {2021},
  doi = {10.3390/jmp2010001}
}
Kostenlos starten →